E

Editas Medicine

CRISPR-based gene editing therapeutics developer

Scientist 1 - Next Generation Sequencing

Translational Research & Bench BiologyConfirmed live in the last 24 hours
ContractCambridge, MA, USA$61 - $65 /hrIn-person

About the Job

Requirements

  • A B.S. or M.S. in molecular biology, genetics, genomics, biochemistry, bioengineering, or a related scientific discipline, with 5–8 years of relevant industry or academic laboratory experience.
  • Demonstrated hands-on experience with next-generation sequencing library preparation and sequencing workflows.
  • Experience operating Illumina sequencing platforms and interpreting sequencing run and library quality-control metrics.
  • Experience designing primers for targeted or amplicon-based sequencing assays.
  • Experience with laboratory automation platforms or automated liquid handling.
  • Demonstrated experience troubleshooting molecular biology or next-generation sequencing workflows and using experimental data to identify and resolve technical issues.
  • Experience developing, optimizing, scaling, or transferring laboratory protocols into routine production workflows.
  • Strong experimental documentation and organizational skills, including experience with electronic laboratory notebooks such as Benchling.
  • Ability to work effectively in a collaborative, multidisciplinary, and timeline-driven environment.
  • Excellent written and verbal communication skills.

Responsibilities

  • Independently execute next-generation sequencing workflows, including sample preparation, library construction, library quality control, sequencing, and initial assessment of sequencing performance and data quality.
  • Perform and optimize Illumina and Oxford Nanopore sequencing workflows supporting gene-editing programs.
  • Analyze sequencing run metrics and assay controls to identify technical issues, determine potential root causes, and recommend experimental next steps.
  • Contribute to the development, optimization, and transition of next-generation sequencing assays into routine production workflows, including implementing automated and semi-automated library preparation methods.
  • Generate and maintain high-quality protocols, experimental records, and technical documentation using systems such as Benchling.
  • Summarize and communicate experimental results through technical reports, presentations, and cross-functional meetings.
  • Maintain awareness of emerging next-generation sequencing technologies and identify opportunities to improve assay quality, throughput, robustness, or efficiency.

Desired Qualifications

  • Experience with Oxford Nanopore sequencing, including library construction and operation of ONT sequencing systems.
  • Experience developing or programming automated workflows.
  • Experience applying next-generation sequencing to CRISPR or other gene-editing applications, including characterization of on-target editing, off-target editing, structural variants, or other editing outcomes.
  • Experience with high-throughput targeted sequencing and multiplexed amplicon assays.
  • Experience with long-read sequencing assay development and optimization.
  • Familiarity with basic next-generation sequencing data analysis, sequencing file formats, and commonly used sequencing quality metrics.
  • Experience using laboratory automation platforms and automated liquid handlers.
  • Experience supporting assay development in a biotechnology or pharmaceutical environment.

About the Company

Editas Medicine

CRISPR-based gene editing therapeutics developer

Editas Medicine develops therapies using CRISPR gene-editing to treat serious diseases. The company advances a pipeline of genomic medicines by discovering, developing, manufacturing, and aiming to commercialize these gene-editing treatments. CRISPR allows scientists to modify DNA in cells to correct genetic defects, and Editas combines this approach with clinical development to bring potential medicines to patients. Unlike firms that focus on other biotechnologies, Editas emphasizes a full drug-development cycle centered on CRISPR-based genomic medicines and partnerships to expand its reach. The company’s goal is to deliver durable, transformative treatments that improve patient outcomes worldwide by moving candidates from discovery through trials to potential approval and commercialization.

Company size
51-200
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2013

Recently Posted Jobs

Explore more opportunities at Editas Medicine

See more jobs